|
|
|
Volumn 9, Issue 45, 2010, Pages 84-89
|
|
Perspectives for personalization in chemotherapy of advanced gastric cancer.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERBB2 PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
CLINICAL TRIAL;
DRUG DESIGN;
DRUG SCREENING;
HUMAN;
METABOLISM;
METHODOLOGY;
ONCOLOGY;
PERSONALIZED MEDICINE;
REVIEW;
STOMACH TUMOR;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS AS TOPIC;
DRUG DESIGN;
DRUG SCREENING ASSAYS, ANTITUMOR;
HUMANS;
INDIVIDUALIZED MEDICINE;
MEDICAL ONCOLOGY;
RECEPTOR, ERBB-2;
STOMACH NEOPLASMS;
TREATMENT OUTCOME;
|
|
EID: 77952573075
PISSN: None
EISSN: 19447930
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (5)
|
|
References (25)
|
